Teva Pharmaceutical Industries' (TEVA) US affiliate Teva Pharmaceuticals and Sanofi (SNY) said Tuesday that a phase 2b study on duvakitug met primary endpoints in patients with ulcerative colitis and Crohn's disease, the most common forms of inflammatory bowel disease.
The companies said 47.8% of ulcerative colitis patients treated with high-dose duvakitug achieved clinical remission at week 14 and 47.8% of Crohn's disease patients on high-dose duvakitug achieved endoscopic response.
Duvakitug was well tolerated, with adverse event rates similar between treatment and placebo groups, the companies added.
Teva and Sanofi said they plan to initiate a phase 3 trial after regulatory discussions. Detailed results of the phase 2b trial are expected to be presented in 2025, they added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。